主要文件

查看所有文档

01885

Docetaxel

Name: Docetaxel
Brand: SIAL

purum, ≥97.0% (HPLC)

别名:

Docetaxel anhydrous

登录查看组织和合同定价。

选择尺寸

变更视图

关于此项目

经验公式（希尔记法）:

C₄₃H₅₃NO₁₄

化学文摘社编号:

114977-28-5

分子量:

807.88

NACRES:

NA.25

PubChem Substance ID:

329747367

UNSPSC Code:

51101929

MDL number:

MFCD00800737

技术服务

需要帮助？我们经验丰富的科学家团队随时乐意为您服务。

让我们为您提供帮助

属性

grade

purum

Quality Level

200

assay

≥97.0% (HPLC)

form

powder or crystals

impurities

~6% water

mp

186-192 °C (dec.)

application(s)

metabolomics
vitamins, nutraceuticals, and natural products

SMILES string

[H][C@@]12C[C@H](O)[C@@]3(C)C(=O)[C@H](O)C4=C(C)[C@H](C[C@@](O)([C@@H](OC(=O)c5ccccc5)[C@]3([H])[C@@]1(CO2)OC(C)=O)C4(C)C)OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c6ccccc6

InChI

1S/C43H53NO14/c1-22-26(55-37(51)32(48)30(24-15-11-9-12-16-24)44-38(52)58-39(3,4)5)20-43(53)35(56-36(50)25-17-13-10-14-18-25)33-41(8,34(49)31(47)29(22)40(43,6)7)27(46)19-28-42(33,21-54-28)57-23(2)45/h9-18,26-28,30-33,35,46-48,53H,19-21H2,1-8H3,(H,44,52)/t26-,27-,28+,30-,31+,32+,33-,35-,41+,42-,43+/m0/s1

InChI key

ZDZOTLJHXYCWBA-VCVYQWHSSA-N

Gene Information

human ... TUBA1A(7846), TUBA1B(10376), TUBA1C(84790), TUBA3C(7278), TUBA3E(112714), TUBA4A(7277), TUBB(203068), TUBB1(81027), TUBB2A(7280), TUBB2B(347733), TUBB3(10381), TUBB4A(10382), TUBB4B(10383), TUBB6(84617), TUBB8(347688)

说明

General description

Docetaxel is a cytotoxic, semisynthetic, second-generation taxane derived from the needles of the European yew tree , with a baccatin ring , and is an anthracycline antibiotic. It is related to paclitaxel but structurally it differs from paclitaxel on the 3′ position of the side chain and 10′ position of the baccatin ring.

Application

Docetaxel has been used:

to test its effect on lysosomal autophagic flux in gastric cancer cells
in combination with stearidonic acid (SDA) to increase its efficacy and enhancing cell death in human prostate cancer cells
as a microtubule-stabilizing agent in prostate and cervical cancer cells
in combination with a γ-secretase inhibitor (GSI) in prostate cancer stem-like cells (PCSCs) to test its effect on the notch signaling pathway

Biochem/physiol Actions

Docetaxel (DOC) is an anti-microtubule agent , a standard anti-cancer drug used in first-line chemotherapy treatment in many types of cancer including prostate and breast cancer. It elicits a stronger effect of inhibiting angiogenesis in both in vitro and in vivo by acting on vascular endothelial growth factor (VEGF) associated with tumor cells. Being involved in many key cellular processes such as cell cycle, angiogenesis, and gene expression; docetaxel interacts with many signaling pathways, such as the epidermal growth factor receptor (EGFR) pathway, Ras pathway, etc.

Docetaxel is a taxane anti-cancer agent related to paclitaxel. It binds to and stabilizes the β−tubulin subunit of microtubules, preventing depolymerization of the mitotic spindle thus leading to cell cycle arrest and apoptosis.

Packaging

Bottomless glass bottle. Contents are inside inserted fused cone.

pictograms

GHS08,GHS07

signalword

Danger

hcodes

H315,H319,H341,H360D,H362,H372

pcodes

P202 - P260 - P263 - P302 + P352 - P305 + P351 + P338 - P308 + P313

Hazard Classifications

Eye Irrit. 2 - Lact. - Muta. 2 - Repr. 1B - Skin Irrit. 2 - STOT RE 1

存储类别

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

ppe

Eyeshields, Gloves, type N95 (US)

法规信息

监管及禁止进口产品

此项目有

历史批次信息供参考:

分析证书(COA)

Lot/Batch Number

BCCK9716

BCCD0505

没有发现合适的版本？

如果您需要特殊版本，可通过批号或批次号查找具体证书。

搜索COA

已有该产品？

在文件库中查找您最近购买产品的文档。

访问文档库

Mode of action of docetaxel - a basis for combination with novel anticancer agents.

Roy S Herbst et al.

Cancer treatment reviews, 29(5), 407-415 (2003-09-16)

Different tumors have different aberrations in signaling and growth stimulation pathways that drive cancer growth. An understanding of these processes is key to the development of new anticancer agents and to identifying optimal treatment strategies and patient populations suitable for

Docetaxel versus active symptom control for refractory oesophagogastric adenocarcinoma (COUGAR-02): an open-label, phase 3 randomised controlled trial.

Hugo E R Ford et al.

The Lancet. Oncology, 15(1), 78-86 (2013-12-18)

Second-line chemotherapy for patients with oesophagogastric adenocarcinoma refractory to platinum and fluoropyrimidines has not shown benefits in health-related quality of life (HRQoL). We assessed whether the addition of docetaxel to active symptom control alone can improve survival and HRQoL for

Docetaxel for treatment of solid tumours: a systematic review of clinical data.

Alberto Montero et al.

The Lancet. Oncology, 6(4), 229-239 (2005-04-07)

Docetaxel is a semisynthetic taxane, a class of anticancer agents that bind to beta tubulin, thereby stabilising microtubules and inducing cell-cycle arrest and apoptosis. Docetaxel was first approved for the treatment of anthracycline-refractory metastatic breast cancer in the mid-1990s. Since

查看所有相关文献

全球贸易项目编号

货号	GTIN
8026040100	04022536374208
PHR3276-3X1.2ML	04065267161006
C19651-100G	04061833474853
C19651-500G	04061833474860
C19651-5G	04061833474877
8026040250	04022536374215
01885-5MG-F	04061838611284
01885-25MG-F	04061838611260